post-bg-496
calendary January 25, 2024

Artificial intelligence in the development of drugs for the treatment of obesity

Eli Lilly, with the participation of biotechnology company Fauna Bio, will develop a new drug for the treatment of obesity. Fauna Bio has an artificial intelligence (AI) platform whose database contains information about the genes of mammals that gain weight before hibernation. Their study will allow us to understand the mechanism of the development of obesity in humans. In total, the Fauna Bio database contains information on the genes of 452 mammal species, 65 of which hibernate.

The company bases its biobank on 22 tissue types from the thirteen-lined ground squirrel (spermophilus tridecemlineatus) taken during its hibernation, resulting in more than 22 billion DNA sequence reads. The weight of these animals doubles due to the accumulation of fat during the summer. Despite this high increase in body fat levels before hibernation, they remain insulin resistant and do not develop hypertension or diabetes.

It is believed that ground squirrels and other hibernating animals have an internal metabolic switch that allows them to control obesity and lose weight in the spring without losing skeletal muscle. The Fauna platform will analyze animal genes to identify the mechanism behind the development of obesity in humans and develop a drug based on this.

Eli Lilly's portfolio includes drugs for the treatment of type 2 diabetes mellitus - Trulicity (dulaglutide) and Mounjaro (tirzepatide).

The company also received FDA approval this year for its obesity drug Zepbound (tirzepatide). The drug is intended for patients over the age of 18 years who are obese (BMI ≥ 30 kg/m2), overweight (BMI ≥ 27 kg/m2) or pathologies associated with excess weight, including hypertension, dyslipidemia, diabetes mellitus type, obstructive apnea, as well as cardiovascular diseases.

The main active component of Zepbound is tirzepatide, which belongs to a new class of drugs known as glucagon-like peptide 1 (GLP-1) receptor agonists. They are used to treat diabetes and obesity.

GLP-1 agonist drugs are also present in Novo Nordisk's portfolio (Wegovy (semaglutide), but Wegovy is inferior to Zepbound in terms of the cost of a monthly course of treatment.

References:
  1. https://pharmvestnik.ru/content/news/FDA-odobrilo-preparat-Eli-Lilly-ot-ojireniya.html

More related posts

new-img-1

Control

Fine for spa resort in Yessentuki

Roszdravnadzor has imposed a fine of 130 thousand rubles on a spa resort in Yessentuki for improper storage of medical products…

03.03.2016
READ ARTICLE
new-img-2

Roszdravnadzor

Roszdravnadzor – patients’ rights

In 2015, Roszdravnadzor restored the rights of more than 460 thousand citizens to effective, accessible, and safe medical…

03.03.2016
READ ARTICLE
new-img-3

Regulation

The certification scheme for medical products hasn’t changed recently

Roszdravnadzor informs that the certification scheme for products in the Russian Federation is determined by Decree of the…

03.04.2016
READ ARTICLE
new-img-4

Control

Fines – Rostov region

In one and a half months of 2016, the Local Agency of Roszdravnadzor in Rostov Region imposed fines of the total amount of…

03.10.2016
READ ARTICLE
new-img-5

Control

Unregistered medical products

Two citizens were fined for selling unregistered medicinal products on the Internet in the Republic of Bashkortostan.

03.10.2016
READ ARTICLE
new-img-6

Control

Unscheduled inspection by roszdravnadzor

Roszdravnadzor started an unscheduled inspection of the Federal State-Funded Institution of Sverdlovsk Region Kirovgrad Central…

03.14.2016
READ ARTICLE
new-img-7

Medical Devices

International medical device regulators forum (IMDRF)

The delegation of the Federal Service for Surveillance in Healthcare headed by Mikhail Murashko, Head of Roszdravnadzor,…

03.17.2016
READ ARTICLE
new-img-8

Pharmaceuticals

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF”

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF” in which pills the metal wire was found.

05.18.2016
READ ARTICLE
new-img-9

Roszdravnadzor

Medical equipment stands idle in the Pskov region

Roszdravnadzor (RZN) statement: the expensive medical equipment for the total amount of 342 million rubles stands idle in…

05.19.2016
READ ARTICLE
new-img-10

Control

Hospital control Jewish autonomous region

Roszdravnadzor has audited the activity of the Regional Budgetary Public Health Facility “Central district hospital of Lenin”…

05.20.2016
READ ARTICLE